Haleon to invest $54 mln in US R&D centre to ... invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.

I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered ...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

Haleon PLC HLN shares slid 1.91% to £3.86 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.10% to 8,638.01. Haleon PLC ...

In this article, we are going to take a look at where Haleon plc (NYSE:HLN) stands against other stocks that lead Monday’s charge amid market bloodbath. The stock market kicked off the trading ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Haleon has named Nathalie Gerschtein as president North America, following Lisa Paley’s announcement to step down from her role. Gerschtein said, “I am honored to join Haleon at such an ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...

(RTTNews) - Pfizer Inc. (PFE) announced the sales of around 618 million ordinary shares in Haleon plc (HLN) at a price of 385 pence or about $5.01 per Ordinary Share for gross proceeds of ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each.

Haleon is to axe diversity targets from its executive bonus scheme in the latest sign that UK businesses are rowing back on DEI. The Sensodyne-maker has confirmed that its chief executive and ...